Cardiomyoplasty review: physiological principles and characteristics of electrically stimulated skeletal muscle. II. A therapeutic option.
Chronic heart failure continues unsolved as ever despite recent advances in cardiac surgery and pharmacological new armamentarium and remains a significant cause of death, regardless of etiology. Cardiomyoplasty (CMP), a new form of biomechanical ventricular support, has given new life to the field of mechanical circulatory support, providing a "bridge" to transplantation and serving as a possible alternative to surgical treatment. The geographic distribution of world experience in 401 patients shows that 80% were centralized in Europe (50%) and South America (30%). This review of the data analysis, documented improved changes in patients clinical status, further clarifies and appropriate patients population indications for DCMP as well as that more than 80% survival probability for NYHA class II & III and an early procedure related mortality of 8 to 10%.
Erdman
S
S
Department of Cardio-Thoracic Surgery, Beilinson Medical Center, Petah Tiqva Israel.
Strasberg
B
B
Invernizzi
C
C
Fiandra
O
O
Moreira
L F
LF
Stolf
N A
NA
D002311:Cardiomyopathy, Dilated / Q000601:surgery; D018421:Cardiomyoplasty; D002598:Chagas Cardiomyopathy / Q000601:surgery; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D000075202:Contraindications; D005069:Evaluation Studies as Topic; D005500:Follow-Up Studies; D006322:Heart Aneurysm / Q000601:surgery; D006333:Heart Failure / Q000145:classification / Q000601:surgery; D006801:Humans; D015337:Multicenter Studies as Topic; D017202:Myocardial Ischemia / Q000601:surgery; D018579:Patient Selection; D011788:Quality of Life; D013997:Time Factors